Skin Cancer

Cemiplimab Gains Breakthrough Tx Designation for Advanced Skin Cancer

By September 08, 2017

A Phase 2, single-arm, open-label clinical trial, EMPOWER-CSCC 1, is now enrolling patients with metastatic CSCC and locally advanced and unresectable CSCC.

<i>MITF</i> p.E318K Prevalence Similar, Regardless of <i>CDKN2A</i>

December 11, 2015

The prevalence of MITF p.E318K is similar in patients with melanoma, irrespective of the presence of CDKN2A mutations, according to a study published online in JAMA Dermatology.

Study Examines Incidence of Non-Melanoma Skin Cancer

March 20, 2015

Incidence of NMSC much higher among Caucasians; Hispanic patients significantly younger

C-Reactive Protein Independent Prognostic Marker in Melanoma

March 18, 2015

Link with overall, melanoma-specific survival; increase in CRP also linked to disease progression

Teledermoscopy Effective for Monitoring Nevi

January 29, 2015

Diagnostic concordance 0.87 between conventional office-based visits, teledermoscopy encounters